ScreenerHero

APRE Aprea Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · aprea.com
0.6050USD-4.80%Mkt Cap: 7.62M $P/E: —

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead prod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.62M USD
Enterprise Value-32.50M USD
Revenue (TTM)5.18K USD
Gross Profit-6.72M USD
Net Income (TTM)-12.60M USD
Revenue/Share0.00 USD
Last Price0.6050 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.87
PEG—
EV/EBITDA2.46
EV/Revenue-6268.93
P/S1543.23
P/B0.20
EPS (TTM)-0.95
EPS (Forward)-0.34
52W Range
0.54805% of range1.690
52W High1.690 USD
52W Low0.5480 USD
Profitability
Gross Margin0.00%
Oper. Margin-255025.51%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-101.27%
ROA-79.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.89M USD
CapEx (TTM)—
FCF Margin-157217.76%
FCF Yield-107.01%
Net Debt-41.23M USD
Net Debt/EBITDA3.12
Balance Sheet
Debt/Equity—
Current Ratio13.55
Quick Ratio13.33
Book Value/Sh3.10 USD
Cash/Share3.27 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateFeb 13, 2023
Analyst Consensus
Rating—
Target (Mean)3.733 USD
Upside (mean)+517.1%
Target Range1.200 USD – 5.000 USD
1.200+517.1% to mean5.000
# Analysts3
Ownership
Shares Out.12.59M
Float7.90M
Insiders9.17%
Institutions18.83%
Short Interest
Short Ratio1.0d
Short % Float4.84%
Short % Out.4.56%
Shares Short574.61K
Short (prev mo.)5.49K
Technical
SMA 500.7295 (-17.1%)
SMA 2000.7871 (-23.1%)
Beta1.63
S&P 52W Chg16.45%
Avg Vol (30d)401.09K
Avg Vol (10d)375.83K
Technical Indicators
RSI (14)32.0
MACD-0.0233
MACD Signal-0.0039
MACD Hist.-0.0195
BB Upper0.8538 USD
BB Middle0.7438 USD
BB Lower0.6337 USD
BB Width29.59%
ATR (14)0.0641 USD
Vol Ratio (20d)0.97x